SCHEDULE: Squadron Master Fund Discloses 9.99% Stake in RELMADA

Squadron Master Fund LP and related entities have disclosed a 9.99% beneficial ownership stake in RELMADA THERAPEUTICS, INC., totaling 7,395,510 shares.

Summary

• Squadron Master Fund LP, along with Squadron Capital Management LLC, William Blank, and Matthew Sesterhenn, reported beneficial ownership of 7,395,510 shares of RELMADA THERAPEUTICS, INC. common stock.
• This ownership represents approximately 9.99% of the company's outstanding common stock.
• The stake includes 6,700,000 shares of common stock and 695,510 shares issuable upon the exercise of warrants held by Squadron Capital Management LLC.
• The reporting persons share both voting and dispositive power over all 7,395,510 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake suggests a vote of confidence in RELMADA THERAPEUTICS, INC. without indicating an activist intent.

Positives

• A significant institutional investor, Squadron Master Fund LP, has taken a substantial 9.99% stake in RELMADA THERAPEUTICS, INC., indicating confidence in the company's long-term prospects.
• The investment includes both direct common stock and warrants, suggesting a strategic long-term position.

Negatives

• The filing itself does not contain any negative information regarding RELMADA THERAPEUTICS, INC.'s performance or outlook.

Risks

• The reporting persons expressly disclaim beneficial ownership over the reported securities, which is a standard legal disclaimer but highlights the indirect nature of their control as investment advisors/managers.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from RELMADA THERAPEUTICS, INC. or the reporting persons regarding the issuer's future performance or strategic direction.

Management Comments

• Squadron Capital Management, LLC, Mr. Blank and Mr. Sesterhenn expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC, Mr. Blank or Mr. Sesterhenn are the beneficial owners of any of the securities reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake, such as the 9.99% disclosed by Squadron Master Fund LP, often signals institutional confidence in a company's long-term value proposition, particularly in the biotechnology or pharmaceutical sector where R&D cycles are long and capital intensive. Such an investment can be viewed positively by the market, potentially attracting further institutional interest.

Comparison to Industry Standards

• A 9.99% stake is a substantial position for an institutional investor, approaching the 10% threshold that would typically trigger a Schedule 13D filing, which implies an intent to influence management. The filing as a 13G indicates a passive investment intent, which is standard for many large institutional holders who do not seek control.
• Compared to activist investors who might take similar stakes in companies like Starboard Value's investments in various underperforming companies, Squadron's filing explicitly states a passive intent, aligning with typical long-term fund strategies rather than activist campaigns.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor may instill greater confidence in the company's stock, potentially leading to increased demand and price stability.
• Company Management: While the filing indicates a passive investment, a large institutional holder can still exert influence through engagement, potentially encouraging sound corporate governance and strategic decisions.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for RELMADA THERAPEUTICS, INC. or the reporting persons beyond the ongoing holding of the disclosed stake.

Key Dates

Recommendation

The disclosure of a substantial 9.99% stake by Squadron Master Fund LP is a positive signal, indicating institutional confidence in RELMADA THERAPEUTICS, INC. However, as a Schedule 13G, it explicitly states a passive investment intent, meaning no immediate activist pressure or strategic changes are implied. While this provides a floor of institutional support, it doesn't inherently suggest new catalysts for significant upside. Therefore, a 'hold' recommendation is appropriate for existing investors, acknowledging the positive institutional backing without anticipating immediate transformative events. New investors might consider initiating a position based on this vote of confidence, but further due diligence on the company's fundamentals is warranted.

Keywords

RELMADA THERAPEUTICS, Squadron Master Fund, Squadron Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Warrants, Equity Stake, Biotechnology, Pharmaceuticals